BIVI News and Press, BioVie Inc. From 09/23/20

SANTA MONICA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it has closed its previously announced underwritten public offering of Class...

SANTA MONICA, CA / ACCESSWIRE / September 21, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that Jonathan Adams, the Company's President & COO, will present at the Oppenheimer Fal...

In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the week's diverse group of IPOs. The year's largest IPO t...

BioVie ( OTCQB:BIVI ) has priced its public offering of 1,565,200 Class A common stock at $10.00/share for aggregate gross proceeds of $15,652,000. More news on: BioVie Inc., Healthcare stocks news, Read more ...

SANTA MONICA, CA / ACCESSWIRE / September 17, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced the pricing of an underwritten public offering of 1,565,200 shares of Class A common stock ...

Hariri, Gorlin, and Rogich to Contribute Their Tremendous Industry Insights and Stature SANTA MONICA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- BioVie, Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies f...

Novel BIV201 Formulation Shows Significant Improvements Over Industry Terlipressin Prefilled Syringe May Significantly Extend Market Protection Beyond Orphan Drug Exclusivity SANTA MONICA, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or &...

SANTA MONICA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVID) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that its first batch of BIV201 prefilled syringes containi...

SANTA MONICA, CA / ACCESSWIRE / October 22, 2019 / BioVie Inc. (OTCQB:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has submitted for assessment by the U.S. Food and Drug Administration ("FDA") the ...

The August lull has set in and we're in the thick of it, with just two pricings this week and one postponement. The IPO pipeline is starting to fill up, with seven companies submitting initial filings led by The We Company (WE), a signal that the summer slowdown is coming to an end. Chinese ...